Who's the biggest winner in this week's run-up of Netflix's stock price?
Poison Pill Defense
Lionsgate, pressured by Carl Icahn's hostile takeover bid, has issued a bullish earnings outlook.
Carl Icahn's decision to launch a hostile takeover of Lionsgate has raised doubts among some financial analysts, who question whether his bid of $6 per share is sufficient.
A group of international institutional shareholders are suing News Corp. and its officers, alleging the company broke a promise that it would not extend a "poison pill" provision beyond 12 months…
More “Poison Pill Defense” on Variety.com